401. Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.
- Author
-
Meyers DE, Adu-Gyamfi B, Segura AM, Buja LM, Mallidi HR, Frazier OH, and Rice L
- Subjects
- Aged, Allografts, Amyloidosis metabolism, Combined Modality Therapy, Female, Graft Rejection mortality, Heart Diseases drug therapy, Humans, Immunoglobulin Light Chains metabolism, Kidney Diseases drug therapy, Lenalidomide, Prognosis, Thalidomide adverse effects, Amyloidosis drug therapy, Graft Rejection chemically induced, Heart Transplantation, Immunologic Factors adverse effects, Kidney Transplantation, Thalidomide analogs & derivatives
- Abstract
We describe a patient who underwent a successful heart and kidney transplant for light-chain amyloidosis. She had an excellent hematologic response to bortezomib/dexamethasone therapy. Follow-up therapy with lenalidomide was started, and the patient quickly had a fatal allograft rejection of the heart and kidney. We present evidence to support the theory that lenalidomide, a known immunomodulator, may have stimulated the immune system and precipitated the fatal rejection episode., (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2013
- Full Text
- View/download PDF